Browse > Article
http://dx.doi.org/10.4014/jmb.1706.06009

Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System  

Ryu, Ji In (Department of Bioscience and Biotechnology, Sejong University)
Wui, Seo Ri (Department of Bioscience and Biotechnology, Sejong University)
Ko, Ara (Department of Bioscience and Biotechnology, Sejong University)
Do, Hien Thi Thu (Department of Bioscience and Biotechnology, Sejong University)
Lee, Yeon Jeong (Department of Bioscience and Biotechnology, Sejong University)
Kim, Hark Jun (Department of Bioscience and Biotechnology, Sejong University)
Rhee, Inmoo (Department of Bioscience and Biotechnology, Sejong University)
Park, Shin Ae (R & D Center, EyeGene)
Kim, Kwang Sung (R & D Center, EyeGene)
Cho, Yang Je (R & D Center, EyeGene)
Lee, Na Gyong (Department of Bioscience and Biotechnology, Sejong University)
Publication Information
Journal of Microbiology and Biotechnology / v.27, no.8, 2017 , pp. 1539-1548 More about this Journal
Abstract
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly causes fatal infections in cystic fibrosis and burn patients as well as in patients who are hospitalized or have impaired immune systems. P. aeruginosa infections are difficult to treat owing to the high resistance of the pathogen to conventional antibiotics. Despite several efforts, no effective prophylactic vaccines against P. aeruginosa are currently available. In this study, we investigated the activity of the CIA06 adjuvant system, which is composed of alum and de-O-acylated lipooligosaccharide, on a P. aeruginosa outer membrane protein (OMP) antigen vaccine in mice. The results indicated that CIA06 significantly increased the antigen-specific IgG titers and opsonophagocytic activity of immune sera against P. aeruginosa. In addition, the antibodies induced by the CIA06-adjuvanted vaccine exhibited higher cross-reactivity with heterologous P. aeruginosa strains. Finally, mice immunized with the CIA06-adjuvanted vaccine were effectively protected from lethal P. aeruginosa challenge. Based on these data, we suggest that the CIA06 adjuvant system might be used to promote the immunogenicity and protective efficacy of the P. aeruginosa OMP vaccine.
Keywords
Pseudomonas aeruginosa; vaccine; adjuvant; de-O-acylated lipooligosaccharide; protective efficacy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 DiGiandomenico A, Rao J, Harcher K, Zaidi TS, Gardner J, Neely AN, et al. 2007. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc. Natl. Acad. Sci. USA 104: 4624-4629.   DOI
2 Bridge DR, Whitmire JM, Makobongo MO, Merrell DS. 2016. Heterologous Pseudomonas aeruginosa O-antigen delivery using a Salmonella enterica serovar Typhimurium wecA mutant strain. Int. J. Med. Microbiol. 306: 529-540.   DOI
3 Rello J, Krenn CG, Locker G, Pilger E, Madl C, Balica L, et al. 2017. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Crit. Care 21: 22.   DOI
4 Ryu JI, Park SA, Wui SR, Ko A, Han JE, Choi JA, et al. 2016. A de-O-acylated lipooligosaccharide-based adjuvant system promotes antibody and Th1-type immune responses to H1N1 pandemic influenza vaccine in mice. Biomed. Res. Int. 2016: 3713656.
5 Inoue K, Hamana Y, Mitsuhashi S. 1995. In vitro antibacterial activity and beta-lactamase stability of a new carbapenem, BO-2727. Antimicrob. Agents Chemother. 39: 2331-2336.   DOI
6 Raymond CK, Sims EH, Kas A, Spencer DH, Kutyavin TV, Ivey RG, et al. 2002. Genetic variation at the O-antigen biosynthetic locus in Pseudomonas aeruginosa. J. Bacteriol. 184: 3614-3622.   DOI
7 Mutharia LM, Nicas TI, Hancock RE. 1982. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J. Infect. Dis. 146: 770-779.   DOI
8 Lee CH, Tsai CM. 1999. Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal. Biochem. 267: 161-168.   DOI
9 Zuercher AW, Horn M P, W u H, S ong Z, Bundg aard C J, Johansen HK, et al. 2006. Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine 24: 4333-4342.   DOI
10 Fabbrini M, Sammicheli C, Margarit I, Maione D, Grandi G, Giuliani MM, et al. 2012. A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus. J. Immunol. Methods 378: 11-19.   DOI
11 Ramos HC, Rumbo M, Sirard JC. 2004. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol. 12: 509-517.   DOI
12 Hamaoka S, Naito Y, Katoh H, Shimizu M, Kinoshita M, Akiyama K. 2017. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia. Microbiol. Immunol. 61: 64-74.   DOI
13 Hassan R, El-Naggar W, Abd El-Aziz AM, Shaaban M, Kenawy HI, Ali YM. 2017. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa. J. Microbiol. Immunol. Infect. DOI: 10.1016/j.jmii.2016.08.014.   DOI
14 Kim DK, Kim JJ, Kim JH, Woo YM, Kim S, Yoon DW, et al. 2000. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine 19: 1274-1283.   DOI
15 Li H, Mo KF, Wang Q, Stover CK, DiGiandomenico A, Boons GJ. 2013. Epitope mapping of monoclonal antibodies using synthetic oligosaccharides uncovers novel aspects of immune recognition of the Psl exopolysaccharide of Pseudomonas aeruginosa. Chemistry 19: 17425-17431.   DOI
16 Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, et al. 2016. Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide. J. Infect. Dis. 213: 640-648.   DOI
17 Sawa T, Ito E, Nguyen VH, Haight M. 2014. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Hum. Vaccin. Immunother. 10: 2843-2852.   DOI
18 Campodonico VL, Llosa NJ, Bentancor LV, Maira-Litran T, Pier GB. 2011. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect. Immun. 79: 3455-3464.   DOI
19 Dakterzada F, Mohabati Mobarez A, Habibi Roudkenar M, Mohsenifar A. 2016. Induction of humoral immune response against Pseudomonas aeruginosa flagellin (1-161) using gold nanoparticles as an adjuvant. Vaccine 34: 1472-1479.   DOI
20 Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. 2001. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147: 2659-2669.   DOI
21 Korn T, Bettelli E, Oukka M, Kuchroo VK. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27: 485-517.   DOI
22 Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, et al. 2008. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J. Immunol. 181: 4965-4975.   DOI
23 Bayes HK, Ritchie ND, Evans TJ. 2016. Interleukin-17 is required for control of chronic lung infection caused by Pseudomonas aeruginosa. Infect. Immun. 84: 3507-3516.   DOI
24 Pan T, Tan R, Li M, Liu Z, Wang X, Tian L, et al. 2016. IL17-producing ${\gamma}$${\delta}$ T cells may enhance humoral immunity during pulmonary Pseudomonas aeruginosa infection in mice. Front. Cell. Infect. Microbiol. 6: 170.
25 Ouyang W, Kolls JK, Zheng Y. 2008. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467.   DOI
26 Rendon JL, Choudhry MA. 2012. Th17 cells: critical mediators of host responses to burn injury and sepsis. J. Leukoc. Biol. 92: 529-538.   DOI
27 Neely CJ, Maile R, Wang MJ, Vadlamudi S, Meyer AA, Cairns BA. 2011. Th17 (IFN${\gamma}$-IL17+) CD4+ T cells generated after burn injury may be a novel cellular mechanism for postburn immunosuppression. J. Trauma 70: 681-690.   DOI
28 Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, et al. 2012. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 186: 420-427.   DOI
29 Banadkoki AZ, Keshavarzmehr M, Afshar Z, Aleyasin N, Fatemi MJ, Behrouz B, et al. 2016. Protective effect of pilin protein with alum+naloxone adjuvant against acute pulmonary Pseudomonas aeruginosa infection. Biologicals 44: 367-373.   DOI
30 Saffari M, Behbood S, Irajian G, Khorshidi A, Moniri R, Behrouz B. 2017. Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds. Biologicals 45: 20-26.   DOI
31 Haghbin M, Armstrong D, Murphy ML. 1973. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer 32: 761-766.   DOI
32 Lam MY, McGroarty EJ, Kropinski AM, MacDonald LA, Pedersen SS, Hoiby N, et al. 1989. Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa. J. Clin. Microbiol. 27: 962-967.
33 Mutharia LM, Nicas TI, Hancock RE. 1982. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J. Infect. Dis. 146: 770-779.   DOI
34 Kim YG, Kim JH, Park WH, Ahn DH, Hong KH, Kim HS, et al. 1994. Protective effect of CFC-101, a Pseudomonas vaccine, in mice. J. Appl. Pharmacol. 2: 322-325.
35 Park WJ, Cho YJ, Ahn DH, Jung SB, Lee NG, Kim HS, et al. 1997. An outer membrane protein preparation as a vaccine against Pseudomonas aeruginosa infection. J. Microbiol. Biotechnol. 7: 144-150.
36 Jang IJ, Kim IS, Park WJ, Yoo KS, Yim DS, Kim HK, et al. 1999. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine 17: 158-168.   DOI
37 Duraisingham SS, Hanson S, Buckland M, Grigoriadou S, Longhurst HJ. 2014. Pseudomonas infection in antibody deficient patients. Eur. J. Microbiol. Immunol. 4: 198-203.   DOI
38 Lee NG, Jung SB, Ahn BY, Kim YH, Kim JJ, Kim DK, et al. 2000. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine 18: 1952-1961.   DOI
39 Kamei A, Wu W, Traficante DC, Koh AY, Van Rooijen N, Pier GB, et al. 2013. Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J. Infect. Dis. 207: 39-49.   DOI
40 Mitsdoerffer M, Lee Y, Jager A, Kim HJ, Korn T, Kolls JK, et al. 2010. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 107: 14292-14297.   DOI
41 Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: 2323-2329.   DOI
42 Gibson RL, Burns JL, Ramsey BW. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168: 918-951.   DOI
43 Han JE, Wui SR, Kim KS, Cho YJ, Cho WJ, Lee NG. 2014. Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide. PLoS One 9: e85838.   DOI
44 Kang CI, K im SH, K im HB, Park SW, Choe Y J, O h MD, et al. 2003. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37: 745-751.   DOI
45 Richards MJ, Edwards JR, Culver DH, Gaynes RP. 2000. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol. 21: 510-515.   DOI
46 Lee NG, Ahn BY, Jung SB, Kim YG, Lee Y, Kim HS, et al. 1999. Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa. FEMS Immunol. Med. Microbiol. 25: 339-347.
47 Doring G, Meisner C, Stern M. 2007. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. USA 104: 11020-11025.   DOI
48 Cho YJ, Ahn BY, Lee NG, Lee DH, Kim DS. 2006. A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine 24: 5862-5871.   DOI
49 Han JE, Kim HK, Park SA, Lee SJ, Kim HJ, Son GH, et al. 2010. A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice. Int. Immunopharmacol. 10: 169-176.   DOI
50 Han JE, Wui SR, Park SA, Lee NG, Kim KS, Cho YJ, et al. 2012. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix TM in mice. Vaccine 30: 4127-4134.   DOI
51 Priebe GP, Goldberg JB. 2014. Vaccines for Pseudomonas aeruginosa: a long and w inding road. Expert Rev. Vaccines 13: 507-519.   DOI
52 Wui SR, Kim HK, Han JE, Kim JM, Kim YH, Chun JH, et al. 2011. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice. Int. Immunopharmacol. 11: 1195-1204.   DOI
53 Wui SR, Han JE, Kim YH, Rhie GE, Lee NG. 2013. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine. Arch. Pharm. Res. 36: 464-471.   DOI
54 Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Available from http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
55 Macvane SH. 2017. Antimicrobial resistance in the intensive care unit: a focus on gram-negative bacterial infections. J. Intensive Care Med. 32: 25-37.   DOI
56 Vincent JL. 2014. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol. 9: 457-463.   DOI
57 Alexander JW, Fisher MW, MacMillan BG. 1971. Immunological control of Pseudomonas infection in burn patients: a clinical evaluation. Arch. Surg. 102: 31-35.   DOI
58 Young LS, Meyer RD, Armstrong D. 1973. Pseudomonas aeruginosa vaccine in cancer patients. Ann. Intern. Med. 79: 518-527.   DOI